Skip to main content
NCBI home page
Springer logoLink to Springer
. 2020 Apr 22;71(8):1567–1574. doi: 10.1007/s12031-020-01532-9

Stability Test of PACAP in Eye Drops

Anita K Kovacs 1, Tamas Atlasz 2,3,✉, Dora Werling 2,4, Edina Szabo 2, Dora Reglodi 2, Gabor K Toth 1
PMCID: PMC8349324  PMID: 32323126

Abstract

PACAP is a neuropeptide with widespread distribution and diverse biological functions. It has strong cytoprotective effects mediated mainly through specific PAC1 receptors. Experimental data show protective effects of PACAP in the retina and cornea in several pathological conditions. Although intravitreal injections are a common practice in some ocular diseases, delivery of therapeutic agents in the form of eye drops would be more convenient and would lead to fewer side effects. We have previously shown that PACAP, in the form of eye drops, is able to pass through the ocular barriers and can exert retinoprotective effects. As eye drops represent a promising form of administration of PACAP in ocular diseases, it is important to investigate the stability of PACAP in solutions used in eye drops. In this study, the stability of PACAP1-27 and PACAP1-38 in eye drops was measured in four common media and a commercially available artificial tear solution at both room temperature and +4 °C. Mass spectrometry results show that the highest stability was gained with PACAP1-38 in water and 0.9% saline solution at +4 °C, representing 80–90% drug persistence after 2 weeks. PACAP1-38 in the artificial tear showed very fast degradation at room temperature, but was stable at +4 °C. In summary, PACAP1-38 has higher stability than PACAP1-27, with highest stability at +4 °C in water solution, but both peptides in each medium can be stored for relatively longer periods without significant degradation. These data can provide reference for future therapeutic use of PACAP in eye drops.

Keywords: PACAP, Eye drops, Stability, Degradation

Introduction

The neuropeptide pituitary adenylate cyclase activating polypeptide (PACAP) exists in two active forms, PACAP1-38 and PACAP1-27, both of which are well-established neuro- and general cytoprotective peptides, with 38 and 27 amino acid residues, respectively (Reglodi et al. 2017, 2018a, b; Shioda and Nakamachi 2015). PACAP1-27 is the form with the shorter C-terminal, representing about 10% of the naturally occurring peptide (Miyata et al. 1990; Vaudry et al. 2009). Both PACAP forms occur in most organs, with the highest expression levels in the nervous system, endocrine glands and testis, but several peripheral organs also have measurable levels of PACAP (Fulop et al. 2019; Horvath et al. 2019; Reglodi et al. 2018c; Vaudry et al. 2009). PACAP and its receptors are also found in ocular tissues, including the lacrimal gland, conjunctiva, inner eye muscles and different layers of the eye. It has been found in all three layers of the eyecup: the fibrous, vascular and nervous layers (Atlasz et al. 2016; Seki et al. 2000a, b). PACAP exerts several different effects in the eye. It affects tear secretion (Nakamachi et al. 2016), influences muscle responses of the iris (Yamaji et al. 2005), increases blood flow in the eye (Dorner et al. 1998) and regulates pigment epithelial cell functions (Fabian et al. 2012, 2019; Maugeri et al. 2019a). Most importantly, as a general protective peptide found not only in the central nervous system but several peripheral organs as well (Laszlo et al. 2019; Liu et al. 2019; Polanco and Pennuto 2018; Reglodi et al. 2018d, e; Shioda et al. 2019; Szegeczki et al. 2019), PACAP has been shown to exert diverse retinoprotective effects in models of toxic, ischemic, inflammatory and traumatic retinal injuries (Atlasz et al. 2016, 2019; Cheng et al. 2018; Endo et al. 2011; Gabriel et al. 2019; Kvarik et al. 2016; Seki et al. 2008; Szabadfi et al. 2016; Vaczy et al. 2016; Ye et al. 2019a, b). Several retinal cell types can be protected by PACAP, including ganglion cells, bipolar neurons, amacrine and pigment epithelial cells (Atlasz et al. 2008; Fabian et al. 2019; Maugeri et al. 2019a; Szabadfi et al. 2012).

PACAP has protective effects not only in the retina, but also in the cornea, where PACAP and its receptors are present in the cornea (Maugeri et al. 2018, 2019b, c; Wang et al. 1995). A few studies have investigated the local effects of PACAP on the cornea. A study in rabbits found that PACAP1-27 eye drops promoted the growth of neuronal processes in the cornea and accelerated recovery of corneal sensitivity (Fukiage et al. 2007). Although it focused only on neuronal recovery, the study drew attention to the possibility that PACAP, in the form of eye drops, could enhance corneal recovery. Indeed, the enhancement of corneal regeneration by topical administration of PACAP was subsequently confirmed in two independent studies (Ma et al. 2015; Nakamachi et al. 2016). PACAP has also demonstrated protective effects on corneal endothelial cells, indicating an important trophic function of the peptide in the cornea (Maugeri et al. 2018, 2019b, c). In in vivo studies, PACAP was given in the form of eye drops in order to exert local effects on the cornea. In contrast, most studies showing retinoprotective effects of the peptide have utilized intravitreal administration. Intravitreal injections, despite their wide clinical use, have the distinct disadvantage of being invasive (Atlasz et al. 2016; Shioda and Nakamachi 2015). Recently, in a model of ischemic retinopathy, we provided evidence that both PACAP forms, given as eye drops, are able to pass through the ocular barriers and reach the retina, where they can exert retinoprotective effects (Werling et al. 2016, 2017). This shows that PACAP treatment as eye drops is a promising therapeutic approach not only in corneal diseases, but also in retinal pathologies. Therefore, it is important to investigate the stability of PACAP in different solutions used in ophthalmic practice. Since the ocular application of PACAP is a potential therapeutic approach in several diseases, including dry eye syndrome (Shioda et al. 2019), the aim of the present study was to analyze the stability of PACAP1-27 and PACAP1-38 in the most commonly used eye drop solvents.

Materials and Methods

Materials

PACAP1-27 and PACAP1-38 were synthesized in our laboratory on a CEM Liberty microwave peptide synthesizer (Matthews, NC, USA) and were dissolved in the following sterile vehicles: (i) 0.9% saline solution, (ii) benzalkonium chloride solution for ophthalmic use (SOCB), (iii) thimerosal solution for ophthalmic use and (iv) water for injection, obtained from the Faculty Central Pharmacy, Faculty of Medicine, University of Szeged. A commercially available artificial tear solution (Systane Ultra®, Alcon, Switzerland) was also used in the experiment.

Analytical reversed-phase high-performance liquid chromatography (RP-HPLC) was performed on an Agilent 1200 Series separation system with diode array and multiple wavelength detector (Waldbronn, Germany), with a Luna C18(2) 100 Å column (10 μm, 250 × 4.6 mm; Phenomenex, Torrance, CA, USA). The chromatography was carried out at room temperature (RT), with a flow rate maintained at 1.2 mL min−1 at a wavelength of 220 nm [mobile phase solvent A: 0.1% TFA in Milli-Q water; solvent B: 0.1% TFA in acetonitrile (AcN)] using gradient elution. Mass spectrometry (MS) data were collected on a Waters SQ Detector (Milford, MA, USA) with an API mass spectrometer in positive ion mode.

Peptide Synthesis and Purification

For the experiment, the synthesized peptides at the University of Szeged (Szeged, Hungary) were as follows: PACAP1-27: H-His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-NH2; PACAP1-38: H-His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2. The sequences were synthesized by a solid-phase technique utilizing Fmoc (fluorenylmethyloxycarbonyl) chemistry. The peptide chains were elongated on a Rink amide MBHA resin (1.1 mmol/g), and the syntheses were carried out using a CEM Liberty microwave peptide synthesizer. The side-chain protecting groups were as follows: Fmoc-His(Trt) (Trt: trityl), Fmoc-Ser(tBu) (tBu: tert-butyl), Fmoc-Asp(tBu), Fmoc-Thr(tBu), Fmoc-Tyr(tBu), Fmoc-Arg(Pbf) (Pbf: 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl), Fmoc-Lys(Boc) (Boc: tert-butyloxycarbonyl). Coupling was performed with HBTU. The completed peptide resins were treated with TFA/water/TIS (93:5:2, v/v) at RT for 2.5 h. The reagents were removed, and the resulting free peptides were solubilized in 10% aqueous acetic acid, filtered and lyophilized. Next, 120–150 mg of crude peptides was dissolved in 1.5 mL 5% m/m acetic acid, and then filtered using a 0.45 μm nylon filter. Gradient elution was used, 20–40% eluent B for 50 min at a flow rate of 3 mL min−1, with detection at 220 nm. Pure fractions were collected and lyophilized to give a white material, with weight of 55–63 mg.

Stability Testing

The stability of the peptides was examined with LC-MS in four media commonly used in ophthalmology: (i) 0.9% saline solution, (ii) benzalkonium chloride solution for ophthalmic use (SOCB), (iii) thimerosal solution for ophthalmic use and (iv) water for injection. First, 0.5 mg peptide was dissolved in 0.5 mL solvent; after dissolution, the resulting liquids were halved. One half of the solvent was cooled to and maintained at +4 °C; the other half was kept at RT. After 3, 6, 8, 11 and 14 days, 40 μL of the given solutions was examined. The stability of PACAP1-38, which showed higher stability in every condition, was also tested in a commercially available artificial tear solution as medium [ingredients: polyethylene glycol 400, propylene glycol, hydroxypropyl guar, sorbitol, aminomethyl propanol, potassium chloride, sodium chloride, 0.001% Polyquad® (polidronium chloride)], following the same protocol.

Results

Table 1 and Figs. 1 and 2 show the stability results for PACAP1-27 in the four media at the two experimental temperatures (RT and +4 °C) over a 2-week period. The results show that at +4 °C, all four solutions have significantly higher stability than the solutions at RT, and the rate of degradation is higher in the SOCB and thimerosal solution than in the other two vehicles (0.9% saline and water). While more than 90% of PACAP1-27 was still intact at +4 °C after 14 days, only 25% remained un-degraded at RT. In contrast, PACAP1-27 was almost completely degraded in benzalkonium chloride solution at RT, while 65% remained intact at the colder temperature.

Table 1.

Stability of PACAP1-27 in different media and conditions over a period of 2 weeks. The numbers in the cells indicate the percentage of the starting material that was not decomposed on the given day

PACAP1-27 0.9% Saline solution Benzalkonium chloride solution for ophthalmic use (SOCB) Thimerosal solution for ophthalmic use Water for injection
RT +4 °C RT +4 °C RT +4 °C RT +4 °C
Day 3 76 96 72 91 49 93 80 98
Day 6 73 91 59 78 44 84 52 95
Day 8 54 89 31 77 30 82 38 92
Day 11 43 83 24 72 27 70 37 91
Day 14 39 79 7 65 22 62 25 90
Open in a new tab

RT room temperature

Fig. 1.

Fig. 1

Open in a new tab

Degradation of PACAP1-27 and PACAP1-38 at room temperature (RT) and at +4 °C in four media (0.9% saline solution, SOCB, thimerosal solution, water for injection) (a–d). We found that all four solutions demonstrated significantly higher stability at +4 °C than at RT, and the rate of degradation was higher in the SOCB and thimerosal solutions than in saline or water vehicles. PACAP1-38 was also more stable than PACAP1-27 in the four media. Degradation of PACAP1-38 in Systane® Ultra at RT and +4 °C (e). Higher stability was found at +4 °C, similar to the other examined media

Fig. 2.

Fig. 2

Open in a new tab

PACAP1-27 initial state tR = 15.14 min (a). The most stable PACAP1-27 after day 14 medium: water for injection, temperature: +4 °C (b). The most degraded PACAP1-27 after day 14 medium: SOCB, temperature: room temperature (c). PACAP1-38 initial state tR = 13.94 min (d). The most stable PACAP1-38 after day 14 medium: water for injection, temperature: +4 °C (e). The most degraded PACAP1-38 after day 14 medium: SOCB, temperature: room temperature (f). Conditions: 0–100% B in 30 min, 220 nm, 1.2 mL/min, eluent A: 0.1% TFA/H2O, eluent B: 80% AcN/0.1% TFA/H2O

PACAP1-38 solutions proved to be more stable than PACAP1-27 in the same four media under the same thermal conditions (Table 2, Figs. 3 and 4). At +4 °C, all four solutions retained more than 90% of PACAP1-38 un-degraded, and even after 2 weeks, more than 90% of the original peptide was measured in saline and water solutions, and more than 75% in the other two solutions.

Table 2.

Stability of PACAP1-38 in different media and conditions over a period of 2 weeks. The numbers in the cells indicate the percentage of the starting material that was not decomposed on the given day

PACAP1-38 0.9% Saline solution Benzalkonium chloride solution for ophthalmic use (SOCB) Thimerosal solution for ophthalmic use Water for injection
RT +4 °C RT +4 °C RT +4 °C RT +4 °C
Day 3 93 99 98 99 96 99 96 100
Day 6 77 99 93 93 84 94 92 99
Day 8 68 96 84 91 77 89 92 95
Day 11 67 93 81 83 73 85 89 94
Day 14 45 92 68 77 64 79 87 91
Open in a new tab

RT room temperature

PACAP1-38 stability was also measured in a commercially available artificial tear solution (Systane® Ultra) at the two experimental temperatures over a 2-week period (Table 3 and Fig. 5). The results showed that the lower temperature gave higher stability, similar to the other examined solutions, but values were worse than in the other solvents during the second week.

Table 3.

Stability of PACAP1-38 in a commercially available artificial tear solution (Systane® Ultra). Numbers in the cells indicate the percentage of the starting material that was not decomposed on the given day

PACAP1-38 Artificial tears (Systane® Ultra)
RT +4 °C
Day 3 75 98
Day 6 58 93
Day 8 37 83
Day 11 24 73
Day 14 12 65
Open in a new tab

RT room temperature

LC-MS measurements showed that a lower temperature (+4 °C) resulted in higher stability for both peptides in all media, but PACAP1-38 had higher stability than PACAP1-27 in all media at both experimental temperatures. Both PACAP1-27 and PACAP1-38 solutions with 0.9% saline solution and water for injection were more stable at both temperatures throughout the 14-day period. We can conclude that the stability of PACAP1-38 and PACAP1-27 was highly medium-dependent. We examined the more stable PACAP1-38 in a commercially available artificial tear solution as medium and found that the stability was lower than in any of the other media. Our findings were confirmed with RP-HPLC profiles of both the initial state and the least and most degraded PACAP1-27 and PACAP1-38 (Figs. 6–11). PACAP1-38 proved to be completely stable in water for injection at +4 °C over a period of 2 weeks (Fig. 10).

Discussion

In the present study we showed the time course of degradation of PACAP1-27 and PACAP1-38 in different solutions at room temperature and at +4 °C. The results show that PACAP1-38 has significantly higher stability than PACAP1-27 at both RT and +4 °C in each medium, with the longest stability in 0.9% saline solution and water for injection.

Naturally occurring or exogenously injected PACAP1-38 and 1-27 are degraded by several peptidases in the blood (Bourgault et al. 2009). Dipeptidyl peptidase IV (DPPIV) cleaves PACAP1-38 to the PAC1 receptor antagonist PACAP3-38 and 5–38 fragments, while PACAP1-27 is more resistant to DPPIV but is readily cleaved by neutral endopeptidase, similar to the structurally homologous VIP. Other enzymes also take part in further cleavage, such as carboxypeptidase and endopeptidase and prohormone convertase (Bourgault et al. 2009; Gourlet et al. 1997).

The therapeutic value of PACAP and/or its derivatives has emerged in light of its strong neuroprotective and general cytoprotective properties as well as potent vasodilatory and several other biological effects (Cline et al. 2019; Jozsa et al. 2019; Parsons and May 2019; Reglodi et al. 2018a; Shioda et al. 2019; Van et al. 2019; Vaudry et al. 2009). PACAP has shown in vivo protective effects in animal models of cerebral ischemia, Parkinson’s and Alzheimer’s disease, Huntington chorea, traumatic brain and spinal cord injury, and different retinal pathologies (Reglodi et al. 2017, 2018b). PACAP passes through the blood–brain barrier (Banks 2016), and therefore, systemic administration can affect the nervous system and lead to neuroprotective effects. Several other routes of administration have been proven to provide protective effects of PACAP in the nervous system and peripheral organs, such as intracerebral, intrathecal, intracerebroventricular, intravitreal and systemic treatments, as well as intravenous, intraperitoneal and subcutaneous administration. Other options include emerging therapeutic approaches such as intranasal and eye drop treatments (Cabezas-Llobet et al. 2018; Meredith et al. 2015; Reglodi et al. 2018a). As far as protection in the eye is concerned, the intravitreal approach is the first choice for treatment in animal models of ocular diseases (Atlasz et al. 2016; Kiss et al. 2006; Reglodi et al. 2018a). This approach has led to the demonstration of the retinoprotective effects of PACAP in models of retinal hypoperfusion (Atlasz et al. 2007), traumatic optic nerve injury (Seki et al. 2008), kainate- and glutamate-induced excitotoxicity (Atlasz et al. 2009; Seki et al. 2006), UV light-induced lesion (Atlasz et al. 2011), lipopolysaccharide-induced inflammation (Vaczy et al. 2018), oxygen-induced retinopathy of prematurity (Kvarik et al. 2016), diabetic retinopathy (D’Amico et al. 2017; Szabadfi et al. 2016) and high intraocular pressure-induced retinopathy (Seki et al. 2011).

Although intravitreal treatments are commonly used in ophthalmological practice, it is an invasive method, with potential side effects and patient discomfort. PACAP, in the form of eye drops, has been shown to lead to extension of neuronal processes from amputated nerve trunks in the cornea following laser-assisted in situ keratomileusis and to accelerate recovery of corneal sensitivity after the surgery (Fukiage et al. 2007). Corneal application of PACAP1-27 eye drops or of a PACAP-derived peptide, with higher stability and PAC1-specific potency than PACAP, also led to enhancement of corneal wound healing in mice (Ma et al. 2015). PACAP treatment in the form of eye drops is also able to increase tear secretion and cAMP and pPKA levels, in addition to the suppression of corneal keratinization and dose-dependent corneal wound healing in mice and rats (Farkas et al. 2010; Nakamachi et al. 2016). We recently showed that both PACAP1-27 and PACAP1-38 given in the form of eye drops could readily cross the ocular surfaces and could reach the retina in a concentration high enough to exert retinoprotective effects in a model of retinal ischemia (Werling et al. 2016, 2017). These results offer a potential novel therapeutic approach to treating retinal diseases. The use of PACAP in eye drops, therefore, would be beneficial not only in corneal diseases, but also in retinal pathologies. The emerging potential of PACAP in the form of eye drops led us to investigate the degradation process of PACAP1-27 and PACAP1-38 in the most commonly used solvents at two different temperatures, room temperature and +4 °C, which are important from both an experimental and clinical perspective. The present results provide a future reference for PACAP solutions to be used in the treatment of ocular disease.

Acknowledgements

This work was supported by the following grants: NAP 2017-1.2.1-NKP-2017-00002, NKFIH129190, Bolyai Scholarship, GINOP-2.3.2-15-2016-00050 “PEPSYS”, MTA-TKI 14016, EFOP-3.6.2-16-2017-00008, EFOP 3.6.1-16.2016.00004, UNKP-19-3-III-PTE-127, UNKP-19-3-1-PTE-137, UNKP-18-4-1-PTE-364, UNKP-16-4-IV, Centre for Neuroscience, PTE AOK Research Grant KA-2017-15, PTE AOK-TANDEM 2019 Grant, “The role of neuro-inflammation in neurodegeneration: from molecules to clinics”; Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary, within the framework of the FIKPII; TUDFO/47138-1/2019-ITM FIKP program.

Funding Information

Open access funding provided by University of Pécs (PTE).

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. Atlasz T, Babai N, Kiss P, et al. Pituitary adenylate cyclase activating polypeptide is protective in bilateral carotid occlusion-induced retinal lesion in rats. Gen Comp Endocrinol. 2007;153:108–114. doi: 10.1016/j.ygcen.2006.12.022. [DOI] [PubMed] [Google Scholar]
  2. Atlasz T, Szabadfi K, Kiss P, et al. PACAP-mediated neuroprotection of neurochemically identified cell types in MSG-induced retinal regeneration. J Mol Neurosci. 2008;36:97–104. doi: 10.1007/s12031-008-9059-5. [DOI] [PubMed] [Google Scholar]
  3. Atlasz T, Szabadfi K, Kiss P, et al. Effects of PACAP in UV-A radiation-induced retinal degeneration models in rats. J Mol Neurosci. 2011;43:51–57. doi: 10.1007/s12031-010-9392-3. [DOI] [PubMed] [Google Scholar]
  4. Atlasz T, Szabadfi K, Reglodi D, et al. Effects of pituitary adenylate cyclase activating polypeptide and its fragments on retinal degeneration induced by neonatal monosodium glutamate treatment. Ann N Y Acad Sci. 2009;1163:348–352. doi: 10.1111/j.1749-6632.2008.03650.x. [DOI] [PubMed] [Google Scholar]
  5. Atlasz T, Vaczy A, Werling D et al (2016) Neuroprotective effects of PACAP in the retina. In: Reglodi D, Tamas A (eds) Pituitary Adenylate Cyclase Activating Polypeptide – PACAP. Springer Nature, New York, pp 501–527
  6. Atlasz T, Werling D, Song S et al (2019) Retinoprotective effects of TAT-bound vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. J Mol Neurosci 68:397–407. 10.1007/s12031-018-1229-5 [DOI] [PMC free article] [PubMed]
  7. Banks WA (2016) Transport of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier: consequences for disease states and therapeutic effects. In: Reglodi D, Tamas A (eds) Pituitary Adenylate Cyclase Activating Polypeptide – PACAP. Springer Nature, New York, pp 423–432
  8. Bourgault S, Vaudry D, Dejda A, Doan ND, Vaudry H, Fournier A. Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective peptide. Curr Med Chem. 2009;16:4462–4480. doi: 10.2174/092986709789712899. [DOI] [PubMed] [Google Scholar]
  9. Cabezas-Llobet N, Vidal-Sancho L, Masana M, Fournier A, Alberch J, Vaudry D, Xifró X (2018) Pituitary adenylate cyclase-activating polypeptide (PACAP) enhances hippocampal synaptic plasticity and improves memory performance in Huntington’s disease. Mol Neurobiol 55:8263–8277. 10.1007/s12035-018-0972-5 [DOI] [PubMed]
  10. Cheng HH, Ye H, Peng RP, Deng J, Ding Y. Inhibition of retinal ganglion cell apoptosis: regulation of mitochondrial function by PACAP. Neural Regen Res. 2018;13:923–929. doi: 10.4103/1673-5374.232489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cline DL, Short LI, Forster MAM, Gray SL. Adipose tissue expression of PACAP, VIP, and their receptors in response to cold stress. J Mol Neurosci. 2019;68:427–438. doi: 10.1007/s12031-018-1099-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. D’Amico AG, Maugeri G, Rasà DM, et al. Modulation of IL-1β and VEGF expression in rat diabetic retinopathy after PACAP administration. Peptides. 2017;97:64–69. doi: 10.1016/j.peptides.2017.09.014. [DOI] [PubMed] [Google Scholar]
  13. Dorner GT, Wolzt M, Eichler HG, Schmetterer L. Effect of pituitary adenylate cyclase activating polypeptide 1-27 on ocular, cerebral and skin blood flow in humans. Naunyn Schmiedeberg’s Arch Pharmacol. 1998;358:657–662. doi: 10.1007/PL00005308. [DOI] [PubMed] [Google Scholar]
  14. Endo K, Nakamachi T, Seki T, et al. Neuroprotective effect of PACAP against NMDA-induced retinal damage in the mouse. J Mol Neurosci. 2011;43:22–29. doi: 10.1007/s12031-010-9434-x. [DOI] [PubMed] [Google Scholar]
  15. Fabian E, Reglodi D, Horvath G et al (2019) Pituitary adenylate cyclase activating polypeptide acts against neovascularization in retinal pigment epithelial cells. Ann N Y Acad Sci. 10.1111/nyas.14189 [DOI] [PubMed]
  16. Fabian E, Reglodi D, Mester L, et al. Effects of PACAP on intracellular signaling pathways in human retinal pigment epithelial cells exposed to oxidative stress. J Mol Neurosci. 2012;48:493–500. doi: 10.1007/s12031-012-9812-7. [DOI] [PubMed] [Google Scholar]
  17. Farkas J, Mester L, Kovacs K et al (2010) Effects of pituitary adenylate cyclase activating polypeptide (PACAP) in corneal epithelial regeneration and signal transduction in rats. Presented at the 5th International Peptide Symposium, December 4–9, 2010 Kyoto, Japan. Abstract
  18. Fukiage C, Nakajima T, Takayama Y, Minagawa Y, Shearer TR, Azuma M. PACAP induces neurite outgrowth in cultured trigeminal ganglion cells and recovery of corneal sensitivity after flap surgery in rabbits. Am J Ophthalmol. 2007;143:255–262. doi: 10.1016/j.ajo.2006.10.034. [DOI] [PubMed] [Google Scholar]
  19. Fulop DB, Humli V, Szepesy J, et al. Hearing impairment and associated morphological changes in pituitary adenylate cyclase activating polypeptide (PACAP)-deficient mice. Sci Rep. 2019;9:14598. doi: 10.1038/s41598-019-50775-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Gabriel R, Postyeni E, Denes V (2019) Neuroprotective potential of pituitary adenylate cyclase activating polypeptide in retinal degenerations of metabolic origin. Front Neurosci 13:1031. 10.3389/fnins.2019.01031 [DOI] [PMC free article] [PubMed]
  21. Gourlet P, Vandermeers A, Robberecht P, Deschodt-Lanckman M. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP-27, but not PACAP-38) degradation by the neutral endopeptidase EC 3.4.24.11. Biochem Pharmacol. 1997;54:509–515. doi: 10.1016/s0006-2952(97)00207-4. [DOI] [PubMed] [Google Scholar]
  22. Horvath G, Opper B, Reglodi D (2019) The neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) is protective in inflammation and oxidative stress-induced damage in the kidney. Int J Mol Sci:20. 10.3390/ijms20194944 [DOI] [PMC free article] [PubMed]
  23. Jozsa G, Fulop BD, Kovacs L et al (2019) Lack of pituitary adenylate cyclase-activating polypeptide (PACAP) disturbs callus formation. J Mol Neurosci. 10.1007/s12031-019-01448-z [DOI] [PMC free article] [PubMed]
  24. Kiss P, Tamás A, Lubics A, et al. Effects of systemic PACAP treatment in monosodium glutamate-induced behavioral changes and retinal degeneration. Ann N Y Acad Sci. 2006;1070:365–370. doi: 10.1196/annals.1317.046. [DOI] [PubMed] [Google Scholar]
  25. Kvarik T, Mammel B, Reglodi D, et al. PACAP is protective in a rat model of retinopathy of prematurity. J Mol Neurosci. 2016;60:179–185. doi: 10.1007/s12031-016-0797-5. [DOI] [PubMed] [Google Scholar]
  26. Laszlo E, Juhasz T, Varga A, et al. Protective effect of PACAP on ischemia/reperfusion-induced kidney injury of male and female rats: gender differences. J Mol Neurosci. 2019;68:408–419. doi: 10.1007/s12031-018-1207-y. [DOI] [PubMed] [Google Scholar]
  27. Liu Y, Lu T, Zhang C et al (2019) Pituitary adenylate cyclase-activating polypeptides prevent hepatocyte damage by promoting yes-associated protein in liver ischemia-reperfusion injury. Transplantation 103:1639–1648. 10.1097/TP.0000000000002742 [DOI] [PMC free article] [PubMed]
  28. Ma Y, Zhao S, Wang X, Shen S, Ma M, Xu W, Hong A. A new recombinant PACAP-derived peptide efficiently promotes corneal wound repairing and lacrimal secretion. Invest Ophthalmol Vis Sci. 2015;56:4336–4349. doi: 10.1167/iovs.15-17088. [DOI] [PubMed] [Google Scholar]
  29. Maugeri G, D’Amico AG, Amenta A et al (2019c) Protective effect of PACAP against ultraviolet B radiation-induced human corneal endothelial cell injury. Neuropeptides. 101978. 10.1016/j.npep.2019.101978 [DOI] [PubMed]
  30. Maugeri G, D’Amico AG, Bucolo C, D’Agata V. Protective effect of PACAP-38 on retinal pigmented epithelium in an in vitro and in vivo model of diabetic retinopathy through EGFR-dependent mechanism. Peptides. 2019;119:170108. doi: 10.1016/j.peptides.2019.170108. [DOI] [PubMed] [Google Scholar]
  31. Maugeri G, D’Amico AG, Castrogiovanni P, et al. PACAP through EGFR transactivation preserves human corneal endothelial integrity. J Cell Biochem. 2019;120:10097–10105. doi: 10.1002/jcb.28293. [DOI] [PubMed] [Google Scholar]
  32. Maugeri G, Longo A, D’Amico AG, et al. Trophic effect of PACAP on human corneal endothelium. Peptides. 2018;99:20–26. doi: 10.1016/j.peptides.2017.11.003. [DOI] [PubMed] [Google Scholar]
  33. Meredith ME, Salameh TS, Banks WA. Intranasal delivery of proteins and peptides in the treatment of neurodegenerative diseases. AAPS J. 2015;17:780–787. doi: 10.1208/s12248-015-9719-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Miyata A, Jiang L, Dahl RD, et al. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38) Biochem Biophys Res Commun. 1990;170:643–648. doi: 10.1016/0006-291X(90)92140-U. [DOI] [PubMed] [Google Scholar]
  35. Nakamachi T, Ohtaki H, Seki T et al (2016) PACAP suppresses dry eye signs by stimulating tear secretion. Nat Commun. 10.1038/ncomms12034 [DOI] [PMC free article] [PubMed]
  36. Parsons RL, May V (2019) PACAP-induced PAC1 receptor internalization and recruitment of endosomal signaling regulate cardiac neuron excitability. J Mol Neurosci 68:340–347. 10.1007/s12031-018-1127-x [DOI] [PMC free article] [PubMed]
  37. Polanco MJ, Pennuto M (2018) Pituitary adenylyl cyclase activating polypeptide (PACAP) signaling and the cell cycle machinery in neurodegenerative diseases. Curr Pharm Des 24:3878–3891. 10.2174/1381612825666181127102311 [DOI] [PubMed]
  38. Reglodi D, Atlasz T, Jungling A, Szabo E, Kovari P, Manavalan S, Tamas A. Alternative routes of administration of the neuroprotective pituitary adenylate cyclase activating polypeptide. Curr Pharm Des. 2018;24:3892–3904. doi: 10.2174/1381612824666181112110934. [DOI] [PubMed] [Google Scholar]
  39. Reglodi D, Atlasz T, Szabo E, et al. PACAP deficiency as a model of aging. Geroscience. 2018;40:437–452. doi: 10.1007/s11357-018-0045-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Reglodi D, Illes A, Opper B, Schafer E, Tamas A, Horvath G (2018c) Presence and effects of pituitary adenylate cyclase activating polypeptide under physiological and pathological conditions in the stomach. Front Endocrinol (Lausanne) 9:90. 10.3389/fendo.2018.00090 [DOI] [PMC free article] [PubMed]
  41. Reglodi D, Renaud J, Tamas A, Tizabi Y, Socías SB, Del-Bel E, Raisman-Vozari R. Novel tactics for neuroprotection in Parkinson’s disease: role of antibiotics, polyphenols and neuropeptides. Prog Neurobiol. 2017;155:120–148. doi: 10.1016/j.pneurobio.2015.10.004. [DOI] [PubMed] [Google Scholar]
  42. Reglodi D, Tamas A, Jungling A, et al. Protective effects of pituitary adenylate cyclase activating polypeptide against neurotoxic agents. Neurotoxicology. 2018;66:185–194. doi: 10.1016/j.neuro.2018.03.010. [DOI] [PubMed] [Google Scholar]
  43. Reglodi D, Vaczy A, Rubio-Beltran E, MaassenVanDenBrink A. Protective effects of PACAP in ischemia. J Headache Pain. 2018;19:19. doi: 10.1186/s10194-018-0845-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Seki T, Itoh H, Nakamachi T, Endo K, Wada Y, Nakamura K, Shioda S. Suppression of rat retinal ganglion cell death by PACAP following transient ischemia induced by high intraocular pressure. J Mol Neurosci. 2011;43:30–34. doi: 10.1007/s12031-010-9410-5. [DOI] [PubMed] [Google Scholar]
  45. Seki T, Itoh H, Nakamachi T, Shioda S. Suppression of ganglion cell death by PACAP following optic nerve transection in the rat. J Mol Neurosci. 2008;36:57–60. doi: 10.1007/s12031-008-9091-5. [DOI] [PubMed] [Google Scholar]
  46. Seki T, Izumi S, Shioda S, Zhou CJ, Arimura A, Koide R. Gene expression for PACAP receptor mRNA in the rat retina by in situ hybridization and in situ RT-PCR. Ann N Y Acad Sci. 2000;921:366–369. doi: 10.1111/j.1749-6632.2000.tb06995.x. [DOI] [PubMed] [Google Scholar]
  47. Seki T, Nakatani M, Taki C, et al. Neuroprotective effect of PACAP against kainic acid-induced neurotoxicity in rat retina. Ann N Y Acad Sci. 2006;1070:531–534. doi: 10.1196/annals.1317.074. [DOI] [PubMed] [Google Scholar]
  48. Seki T, Shioda S, Izumi S, Arimura A, Koide R. Electron microscopic observation of pituitary adenylate cyclase activating polypeptide (PACAP)-containing neurons in the rat retina. Peptides. 2000;21:109–113. doi: 10.1016/S0196-9781(99)00180-1. [DOI] [PubMed] [Google Scholar]
  49. Shioda S, Nakamachi T. PACAP as a neuroprotective factor in ischemic neuronal injuries. Peptides. 2015;72:202–207. doi: 10.1016/j.peptides.2015.08.006. [DOI] [PubMed] [Google Scholar]
  50. Shioda S, Takenoya F, Hirabayashi T, Wada N, Seki T, Nonaka N, Nakamachi T. Effects of PACAP on dry eye symptoms, and possible use for therapeutic application. J Mol Neurosci. 2019;68:420–426. doi: 10.1007/s12031-018-1087-1. [DOI] [PubMed] [Google Scholar]
  51. Szabadfi K, Atlasz T, Kiss P, et al. Protective effects of the neuropeptide PACAP in diabetic retinopathy. Cell Tissue Res. 2012;348:37–46. doi: 10.1007/s00441-012-1349-0. [DOI] [PubMed] [Google Scholar]
  52. Szabadfi K, Reglodi D, Szabo A, et al. Pituitary adenylate cyclase activating polypeptide, a potential therapeutic agent for diabetic retinopathy in rats: focus on the vertical information processing pathway. Neurotox Res. 2016;29:432–446. doi: 10.1007/s12640-015-9593-1. [DOI] [PubMed] [Google Scholar]
  53. Szegeczki V, Bauer B, Jungling A, et al. Age-related alterations of articular cartilage in pituitary adenylate cyclase-activating polypeptide (PACAP) gene-deficient mice. Geroscience. 2019;41:775–793. doi: 10.1007/s11357-019-00097-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Vaczy A, Kovari P, Kovacs K, et al. Protective role of endogenous PACAP in inflammation-induced retinal degeneration. Curr Pharm Des. 2018;24:3534–3542. doi: 10.2174/1381612824666180924141407. [DOI] [PubMed] [Google Scholar]
  55. Vaczy A, Reglodi D, Somoskeoy T, et al. The protective role of PAC1-receptor agonist maxadilan in BCCAO-induced retinal degeneration. J Mol Neurosci. 2016;60:186–194. doi: 10.1007/s12031-016-0818-4. [DOI] [PubMed] [Google Scholar]
  56. Van C, Condro MC, Lov K et al (2019) PACAP/PAC1 regulation of inflammation via catecholaminergic neurons in a model of multiple sclerosis. J Mol Neurosci 68:439–451. 10.1007/s12031-018-1137-8 [DOI] [PMC free article] [PubMed]
  57. Vaudry D, Falluel-Morel A, Bourgault S, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev. 2009;61:283–357. doi: 10.1124/pr.109.001370. [DOI] [PubMed] [Google Scholar]
  58. Wang ZY, Alm P, Hakanson R. Distribution and effects of pituitary adenylate cyclase-activating peptide in the rabbit eye. Neuroscience. 1995;69:297–308. doi: 10.1016/0306-4522(95)00258-K. [DOI] [PubMed] [Google Scholar]
  59. Werling D, Banks WA, Salameh TS et al (2017) Passage through the ocular barriers and beneficial effects in retinal ischemia of topical application of PACAP1–38 in rodents. Int J Mol Sci 18(3) pii: E675. 10.3390/ijms18030675 [DOI] [PMC free article] [PubMed]
  60. Werling D, Reglodi D, Banks WA, et al. Ocular delivery of PACAP1-27 protects the retina from ischemic damage in rodents. Invest Ophthalmol Vis Sci. 2016;57:6683–6691. doi: 10.1167/iovs.16-20630. [DOI] [PubMed] [Google Scholar]
  61. Yamaji K, Yoshitomi T, Usui S. Action of biologically active peptides on monkey iris sphincter and dilator muscles. Exp Eye Res. 2005;80:815–820. doi: 10.1016/j.exer.2004.12.020. [DOI] [PubMed] [Google Scholar]
  62. Ye D, Shi Y, Xu Y, Huang J. PACAP attenuates optic nerve crush-induced retinal ganglion cell apoptosis via activation of the CREB-Bcl-2 pathway. J Mol Neurosci. 2019;68:475–484. doi: 10.1007/s12031-019-01309-9. [DOI] [PubMed] [Google Scholar]
  63. Ye D, Yang Y, Lu X, Xu Y, Shi Y, Chen H, Huang J. Spatiotemporal expression changes of PACAP and its receptors in retinal ganglion cells after optic nerve crush. J Mol Neurosci. 2019;68:465–474. doi: 10.1007/s12031-018-1203-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Molecular Neuroscience are provided here courtesy of Springer

RESOURCES